SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) — Tricida, Inc. (TCDA) announced today that it will release its second quarter 2022 financial results after market close on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss its second quarter financial results and business progress. The webcast or call can be accessed as follows:
Tricida Second Quarter Financial Results Conference Call
Monday, August 8, 2022
4:30 p.m. Eastern Time
A replay of the webcast will be available on the Tricida website approximately two hours after the call ends and will be available for up to 90 days after the presentation.
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, an unabsorbed orally administered polymer designed to slow the progression of CKD in patients with metabolic acidosis and IRC. Tricida is currently conducting a renal outcome clinical trial, VALOR-CKD, to determine whether veverimer slows the progression of CKD in patients with metabolic acidosis and CKD. Metabolic acidosis is a common condition caused by CKD and is thought to accelerate the progression of kidney damage. It is estimated to pose a health risk to approximately 4.3 million CKD patients in the United States. There are currently no FDA-approved treatments to slow the progression of kidney disease by correcting chronic metabolic acidosis in patients with CKD.
For more information on Tricida, please visit www.Tricida.com.
Senior Vice President of Investor Relations and Communications
Source: Tricida, Inc.